10月6日，查尔斯河盘中上涨5.24%，报327.04美元/股，成交额4321.05万美元。消息面上，瑞银于9月30日将公司评级从中性上调至买入，目标价从175美元大幅提升至357美元，显著高于市场平均目标价，提振了投资者信心。
同时，公司当日宣布与Autolomous联合推出数字化实验室执行能力，依托autoloMATE系统对北美和欧洲生物制剂测试基地进行数字化改造，聚焦GMP质量控制检测，推动实验流程自动化并实现全链路数据追溯，进一步强化了公司在生命科学服务领域的竞争力。
此外，公司近期在GLP-1相关检测、疫苗研发合作等多个领域持续拓展业务，叠加此前摩根大通、Evercore ISI等机构亦相继上调目标价，市场对公司长期增长前景的预期持续升温。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.